Cost-effectiveness of pre-emptive pharmacogenetic testing: An umbrella review
Taichi Ochi, Manon G den Uil, Greta Piazza, Geert W J Frederix, Eelko Hak, Vera H M Deneer, Talitha L Feenstra · 2026
Read Cost-effectiveness of pre-emptive pharmacogenetic testing: An umbrella review by Taichi Ochi, Manon G den Uil, Greta Piazza, Geert W J Frederix, Eelko Hak, Vera H M Deneer, Talitha L Feenstra (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0338277.txt.
Description
Testing a patient's genes before prescribing can prevent bad drug reactions, but health systems ask whether the tests pay for themselves. Taichi Ochi and colleagues gathered seventeen earlier systematic reviews on that question into one umbrella review, published in PLOS One in 2026.
Searches across three databases, with a fresh update in 2025, fed the summary, and each review's quality was graded with a standard checklist. As the number of studies has grown, the balance of evidence has leaned toward the tests being worth their cost in several drug areas. The authors say cost questions should no longer block careful rollout where guidelines already support testing.
Catalog record
| CREATOR | Taichi Ochi, Manon G den Uil, Greta Piazza, Geert W J Frederix, Eelko Hak, Vera H M Deneer, Talitha L Feenstra |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46259 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |